Roxanne Lagano Sells 9,797 Shares of Zoetis Inc. (ZTS) Stock
Zoetis Inc. (NYSE:ZTS) insider Roxanne Lagano sold 9,797 shares of Zoetis stock in a transaction that occurred on Tuesday, November 8th. The shares were sold at an average price of $50.43, for a total transaction of $494,062.71. Following the completion of the transaction, the insider now owns 8,063 shares of the company’s stock, valued at $406,617.09. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Shares of Zoetis Inc. (NYSE:ZTS) opened at 51.09 on Friday. Zoetis Inc. has a 1-year low of $38.26 and a 1-year high of $53.14. The firm has a 50-day moving average of $50.71 and a 200 day moving average of $49.43. The company has a market capitalization of $25.23 billion, a P/E ratio of 36.83 and a beta of 1.05.
Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Wednesday, November 2nd. The company reported $0.52 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.46 by $0.06. The firm earned $1.20 billion during the quarter, compared to analysts’ expectations of $1.22 billion. Zoetis had a net margin of 14.10% and a return on equity of 72.96%. The company’s revenue for the quarter was up 2.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.50 earnings per share. On average, analysts anticipate that Zoetis Inc. will post $1.93 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Thursday, November 3rd will be paid a $0.095 dividend. The ex-dividend date is Tuesday, November 1st. This represents a $0.38 dividend on an annualized basis and a dividend yield of 0.74%. Zoetis’s dividend payout ratio (DPR) is presently 27.54%.
ZTS has been the subject of a number of recent research reports. Guggenheim reiterated a “buy” rating and issued a $60.00 price objective on shares of Zoetis in a research note on Monday, July 18th. Barclays PLC lifted their price objective on shares of Zoetis from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Thursday, August 4th. Citigroup Inc. boosted their price target on shares of Zoetis from $50.00 to $53.00 and gave the company a “neutral” rating in a research report on Thursday, August 4th. Jefferies Group boosted their price target on shares of Zoetis from $58.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday, August 4th. Finally, Credit Suisse Group AG restated an “outperform” rating and set a $60.00 price target on shares of Zoetis in a research report on Tuesday, August 23rd. Two research analysts have rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Zoetis currently has an average rating of “Buy” and a consensus price target of $55.92.
Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Zoetis by 6.5% in the second quarter. Vanguard Group Inc. now owns 29,819,968 shares of the company’s stock worth $1,415,256,000 after buying an additional 1,812,428 shares during the period. BlackRock Institutional Trust Company N.A. boosted its stake in shares of Zoetis by 7.1% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 12,516,447 shares of the company’s stock worth $650,980,000 after buying an additional 830,200 shares during the period. Independent Franchise Partners LLP boosted its stake in shares of Zoetis by 1.6% in the third quarter. Independent Franchise Partners LLP now owns 11,361,033 shares of the company’s stock worth $590,887,000 after buying an additional 177,286 shares during the period. Principal Financial Group Inc. boosted its stake in shares of Zoetis by 1.3% in the third quarter. Principal Financial Group Inc. now owns 10,016,876 shares of the company’s stock worth $520,978,000 after buying an additional 126,708 shares during the period. Finally, Marshall Wace LLP boosted its stake in shares of Zoetis by 1.9% in the second quarter. Marshall Wace LLP now owns 9,159,978 shares of the company’s stock worth $434,733,000 after buying an additional 173,902 shares during the period. 93.28% of the stock is owned by hedge funds and other institutional investors.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.